Shares of Regeneron Pharmaceuticals Inc. REGN, +1.56% gained 3.2% in premarket trading on Friday after the company said its COVID-19 antibody cocktail treatment generated $145.5 million in sales in the fourth quarter of 2020 as part of its earnings. The treatment, which received emergency use authorization in the U.S. in November, generated $185.7 million in sales for the full year. The U.S. government has agreed to buy up to about 1.5 million doses of the therapy, a purchase that brings in roughly $2.6 billion in revenue for Regeneron, the company said Friday. Regeneron’s stock has rallied 34.0% over the past 12 months, while the broader S&P 500 SPX, +1.09% is up 17.4%.
View Article Origin Here
